Personalis, Inc. reported record quarterly revenue of $20.9 million in the first quarter of 2021, a 9% increase compared to the first quarter of 2020. The company's revenue from biopharma and all other customers, excluding VA MVP, grew 74% year-over-year.
Record quarterly revenue of $20.9 million, a 9% increase year-over-year.
Revenue from biopharma and all other customers, excluding VA MVP, increased by 74% year-over-year.
Announced collaborations with Natera and MapKure.
Added approximately $162 million of cash from a public offering, ending the quarter with $353.4 million in cash, cash equivalents, and short-term investments.
Personalis expects total company revenues of approximately $21.3 million and a net loss in the range of $16 million to $17 million for the second quarter of 2021. For the full year 2021, the company anticipates total company revenues of approximately $85 million and a net loss in the range of $70 million to $75 million.
Analyze how earnings announcements historically affect stock price performance